Allergen immunotherapy on the way to product-based evaluation - a WAO statement

World Allergy Organization Journal

Volumn 8, Issue 1, 2015, Pages

  Bachert, Claus ^a   Larché, Mark ^b   Bonini, Sergio ^c   Canonica, Giorgio Walter ^d   Kündig, Thomas ^e   Larenas Linnemann, Desiree ^f   Ledford, Dennis ^g   Neffen, Hugo ^h   Pawankar, Ruby ⁱ   Passalacqua, Giovanni ^d  

^a GHENT UNIVERSITY   (Belgium)

^b ST JOSEPH S HOSPITAL   (Canada)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^f LIVER RESEARCH UNIT   (Mexico)

^g UNIVERSITY OF SOUTH FLORIDA   (United States)

^h 'O Alassia' Children's Hospital   (Argentina)

ⁱ NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN;

ALLERGEN IMMUNOTHERAPY; ALLERGIC RHINITIS; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; DRUG ADMINISTRATION ROUTE; DRUG SURVEILLANCE PROGRAM; EVIDENCE BASED MEDICINE; HUMAN; IMMUNOTHERAPY; OUTCOME ASSESSMENT; PATIENT MONITORING; PATIENT SAFETY; PRIORITY JOURNAL; PRODUCT SAFETY; RISK REDUCTION; THERAPY EFFECT;

EID: 84941761836     PISSN: None     EISSN: 19394551     Source Type: Journal    
DOI: 10.1186/s40413-015-0078-8     Document Type: Article

References (19)

1. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63:8-160.
2. Bousquet J, Lockey R, Malling HJ. World Health Organization Position Paper: Allergen immunotherapy: therapeutical vaccines for allergic diseases. Allergy. 1998;53(supp):1-33.
3. Canonica GW, Cox L, Pawankar R, Baena-Cagnani CE, Blaiss M, Bonini S, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J. 2014;7:6.
4. Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011;127(1 suppl):1-55.
5. Passalacqua G. Specific immunotherapy: beyond the clinical scores. Ann Allergy Asthma Immunol. 2011;107:401-6.
6. Calderon MA, Demoly P, Gerth van Wijk R, Bousquet J, Sheikh A, Frew A, et al. EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy. Clin Transl Allergy. 2012;2:20.
7. Calderon MA, Andersen JS, Nelson HS. Are meta-analysis-based comparisons solid evidence? J Allergy Clin Immunol. 2013;132:506-8.
8. Bachert C, Canonica GW, Bufe A. SIT: efficacy depends on product, not on route of application. Pediatr Allergy Immunol. 2012;23:401.
9. Baena-Cagnani CE, Larenas Linnemann D, Gómez M, Díaz SG, Solé D, Borges MS, et al. SLAAI Immunotherapy Working Group. Allergy training and immunotherapy in Latin America: results of a regional overview. Ann Allergy Asthma Immunol. 2013;111:415-9.
10. Cox L, Jacobsen L. Comparison of allergen immunotherapy practice patterns in the United States and Europe. Ann Allergy Asthma Immunol. 2009;103:451-59.
11. Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S. Sublingual mmunotherapy with once-daily grass-allergen tablets: a randomised controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006;117:802-9.
12. Didier A, Malling HJ, Worm M, Horak F, Jager S, Montagut A, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol. 2007;120:138-45.
13. Creticos PS, Maloney J, Bernstein DI, Casale T, Kaur A, Fisher R, et al. Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults. J Allergy Clin Immunol. 2013;131:1342-9.
14. Pfaar O, Demoly P, Gerth van Wijk R, Bonini S, Bousquet J, Canonica GW, et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. Allergy. 2014;69:854-67.
15. Canonica GW, Baena-Cagnani CE, Bousquet J, Bousquet PJ, Lockey RF, Malling HJ, et al. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy. 2007;62:317-24.
16. Kaul S, May S, Lüttkopf D, Vieths S. Regulatory environment for allergen-specific immunotherapy. Allergy. 2011;66:753-64.
17. Lorenz AR, Luttkopf D, Seitz R, Vieths S. The regulatory system in Europe with special emphasis on allergen products. Int Arch Allergy Immunol. 2008;147:263-75.
18. European Medicines Agency. Commitee for medicinal products for human use (CHMP). Guideline on the Clinical Development of Products for Specific Immunotherapy for The Treatment of Allergic Diseases. 2008
19. Bonini S. Regulatory Aspects of Allergen-Specific Immunotherapy: Europe Sets the Scene for a Global Approach. WAO J. 2012;5:120-3.